Safety outcomes
cataract, endophthalmitis, loss of vision
PROLIFERATIVE DIABETIC RETINOPATHY, ISCHAEMIC HEART DISEASE, ENDOPHTHALMITIS, CATARACT, CEREBROVASCULAR ACCIDENT, VITREOUS HAEMORRHAGE, LOSS OF VISION
Rescue focal macular laser was required for two eyes from the combination treatment arm and one eye in the aflibercept only group. One eye from each treatment arm developed a small vitreous haemorrhage due to the injection procedure. No eyes developed endophthalmitis or proliferative diabetic retinopathy. One eye in the monotherapy arm had worsening of cataract. Three eyes (11%) of the combination therapy group had >15 letter loss of vision (One patient in the combination therapy group was admitted to hospital for management of ischaemic heart disease. No patient had a cerebrovascular accident.